Jim Simons Aadi Bioscience, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 543,722 shares of AADI stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

543,722

Previous 398,722 36.37%

Holding current value

$1.04 Million

Previous $805,000 58.01%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.59 - $2.44 $230,550 - $353,800	145,000 Added 36.37%	543,722 $1.27 Million
Q4 2023 Feb 13, 2024	BUY	$1.97 - $5.41 $301,016 - $826,648	152,800 Added 62.13%	398,722 $805,000
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $202,312 - $298,034	41,800 Added 20.48%	245,922 $1.19 Million
Q2 2023 Aug 11, 2023	SELL	$6.84 - $8.56 $831,757 - $1.04 Million	-121,602 Reduced 37.33%	204,122 $1.4 Million
Q1 2023 May 12, 2023	BUY	$6.85 - $13.0 $510,338 - $968,526	74,502 Added 29.66%	325,724 $2.36 Million

Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $87,527 - $105,850	7,300 Added 2.99%	251,222 $3.22 Million
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $846,912 - $1 Million	70,400 Added 40.57%	243,922 $3.45 Million
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $393,380 - $609,280	34,000 Added 24.37%	173,522 $2.14 Million
Q1 2022 May 13, 2022	BUY	$16.65 - $24.97 $183,149 - $274,670	11,000 Added 8.56%	139,522 $2.37 Million
Q4 2021 Feb 11, 2022	SELL	$19.32 - $29.02 $717,409 - $1.08 Million	-37,133 Reduced 22.42%	128,522 $3.1 Million
Q3 2021 Nov 12, 2021	BUY	$25.52 - $41.85 $4.23 Million - $6.93 Million	165,655 New	165,655 $4.87 Million

Others Institutions Holding AADI

# of Institutions

Shares Held

13.7M

Call Options Held

4.9K

Put Options Held

700

View Full List

About Aadi Bioscience, Inc.

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $40.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

More about AADI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account